Highest-materiality recent filing
Genelux enters $100M at-the-market equity offering agreement with TD Cowen
Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.
Genelux prices $20M public offering of 6.7M shares at $3.00
Priced underwritten public offering of 6,666,667 shares at $3.00 each.
Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares
Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.
Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC
Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share
Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.
Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option
Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.
Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00
Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.
Genelux: Olvi-Vec estimated billion+ US market; interim data in recurrent NSCLC expected mid-2024
Olvi-Vec estimated to represent more than $1 billion annual US market opportunity.
Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026
Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.
Genelux Corp raises ~$18M in private placement of 900K shares at $20/share
Gross proceeds ~$18M from sale of 900K shares of common stock at $20 per share.
Genelux closes $15M IPO at $6.00/share; reprices stock options to IPO price
IPO of 2,500,000 shares at $6.00/share closed Jan 30, 2023; gross proceeds ~$15M.
On February 3, 2025, the Company announced the appointment of Matt Pulisic as the Company’s Chief Financial Officer, effective as of January 30, 2025 (the “ Effective Date ”).
On January 29, 2025 (the “ Separation Date ”), Lourie Zak resigned as Chief Financial Officer of Genelux Corporation (the “ Company ”), effective immediately.
On September 23, 2024, Caroline Jewett notified Genelux Corporation (the “Company”) of her resignation as Vice President, Head of Quality of the Company, effective as of October 18, 2024.
On November 21, 2023, Doug Samuelson resigned as VP, Finance of Genelux Corporation effective as of November 21, 2023.
Thomas Zindrick, the Company’s President and Chief Executive Officer, will no longer serve as the Company’s principal financial officer
Doug Samuelson, the Company’s former Chief Financial Officer, will no longer serve as the Company’s principal accounting officer
On August 28, 2023, Genelux Corporation (the “ Company ”) announced the appointment of Lourie Zak as the Company’s Chief Financial Officer and the designation of Ms. Zak as the Company’s principal financial officer and principal accounting officer
Gabe Woodward notified the board of directors (the “Board”) of Genelux Corporation (the “Company”) of his decision to resign from the Board, effective July 12, 2023.
Max materiality 0.85 · Median 0.50 · Most common event other_material